J. Broséus, S. Mourah, and G. Ramstein, VEGF121 is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers, Oncotarget, vol.8, issue.53, pp.90808-90824, 2017.

J. Broséus, G. Chen, and S. Hergalant, Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses, Oncotarget, vol.7, issue.51, pp.83987-84002, 2016.

J. Broséus, J. H. Park, and S. Carillo, Presence of calreticulin mutations in JAK2-negative polycythemia vera, Blood, vol.124, issue.26, pp.3964-3970, 2014.

J. Broséus, T. Alpermann, and M. Wulfert, Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis, Leukemia, vol.27, issue.9, pp.1826-1831, 2013.

J. Broséus, L. Florensa, and E. Zipperer, Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis, Haematologica, vol.97, issue.7, pp.1036-1077, 2012.

C. Manenq, J. F. Lesesve, N. Dreumont, F. Massin, S. Salignac et al., Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow, Int J Lab Hematol, vol.42, pp.52-60, 2020.

M. Divoux, A. Plocque, M. Sevin, L. Voillat, A. Guerci-bresler et al., Efficacy of Lenalidomide in Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and an extreme platelet count. Clin Case Rep

C. Moulin, R. Morizot, T. Remen, H. Augé, F. Bouclet et al., Clinical and Biological Characteristics and Outcomes of Richter Transformation: A French Multicenter Study from the Filo Group, Annual meeting of the, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02427541

M. Maynadié, F. Girodon, I. Manivet-janoray, M. Mounier, F. Mugneret et al., Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or, Haematologica, vol.96, issue.1, pp.55-61, 2011.

J. Vardiman, R. Brunning, D. Arber, L. Beau, M. Porwit et al., World Health Organization Classification of tumours of haematopoietic and lymphoid tissues 4th ed, pp.18-30, 2008.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-405, 2016.

C. James, U. V. , L. Couédic, J. P. Staerk, J. Delhommeau et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.434, issue.7037, pp.1144-1152, 2005.

E. J. Baxter, L. M. Scott, P. J. Campbell, C. East, N. Fourouclas et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, vol.365, issue.9464, pp.1054-61, 2005.

R. Kralovics, F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt et al., A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, vol.352, issue.17, pp.1779-90, 2005.

R. L. Levine, M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-97, 2005.

M. Boissinot, R. Garand, M. Hamidou, and S. Hermouet, The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS), Blood, vol.108, issue.5, pp.1781-1783, 2006.

M. M. Ceesay, N. C. Lea, W. Ingram, N. B. Westwood, J. Gäken et al., The JAK2 V617F mutation is rare in RARS but common in RARS-T, Leukemia, vol.20, issue.11, pp.2060-2061, 2006.

A. F. Remacha, J. F. Nomdedéu, G. Puget, C. Estivill, M. P. Sarda et al., Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiablerefractory anemia with ringed sideroblasts associated with marked thrombocytosis, Haematologica, vol.91, issue.5, pp.719-739, 2006.

A. Renneville, B. Quesnel, A. Charpentier, L. Terriou, A. Crinquette et al., High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Leukemia, vol.20, issue.11, pp.2067-70, 2006.

D. P. Steensma, J. S. Caudill, A. Pardanani, R. F. Mcclure, T. L. Lasho et al., MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count, Haematologica, vol.91, issue.12, p.57, 2006.

H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. D. Hsi et al., Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation, Blood, vol.108, issue.7, pp.2173-81, 2006.

S. A. Wang, R. P. Hasserjian, J. M. Loew, E. V. Sechman, D. Jones et al., Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features, Leukemia, vol.20, issue.9, pp.1641-1645, 2006.

N. Gattermann, J. Billiet, R. Kronenwett, E. Zipperer, U. Germing et al., High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable, Blood, vol.109, issue.3, pp.1334-1339, 2007.

, Dr Julien BROSÉUS, vol.113, issue.124

J. M. Raya, L. Arenillas, A. Domingo, B. Bellosillo, G. Gutiérrez et al., Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status, Int J Hematol, vol.88, issue.4, pp.387-95, 2008.

A. D. Pardanani, R. L. Levine, T. Lasho, Y. Pikman, R. A. Mesa et al., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3478, 2006.

S. Schnittger, U. Bacher, C. Haferlach, R. Dengler, A. Kröber et al., Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis, Leukemia, vol.22, issue.2, pp.453-458, 2008.

N. C. Cross, Genetic and epigenetic complexity in myeloproliferative neoplasms, Hematology Am Soc Hematol Educ Program, pp.208-222, 2011.

T. Klampfl, H. Gisslinger, A. S. Harutyunyan, H. Nivarthi, E. Rumi et al., Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, N Engl J Med, 2013.

J. Nangalia, C. E. Massie, E. J. Baxter, F. L. Nice, G. Gundem et al., Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2, N Engl J Med, 2013.

D. Pietra, E. Rumi, V. V. Ferretti, C. A. Buduo, C. Milanesi et al., Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms, Leukemia, vol.30, issue.2, pp.431-439, 2016.

C. Marty, C. Pecquet, H. Nivarthi, M. El-khoury, I. Chachoua et al., Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis, Blood, vol.127, issue.10, pp.1317-1341, 2016.

M. Araki, Y. Yang, N. Masubuchi, Y. Hironaka, H. Takei et al., Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms, Blood, vol.127, issue.10, pp.1307-1323, 2016.

I. Chachoua, C. Pecquet, M. El-khoury, H. Nivarthi, R. I. Albu et al., Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants, Blood, vol.127, issue.10, pp.1325-1360, 2016.

M. Cazzola, Mutant calreticulin: when a chaperone becomes intrusive, Blood, vol.127, issue.10, pp.1219-1240, 2016.

F. Girodon, F. Dutrillaux, J. Broséus, M. Mounier, V. Goussot et al., Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients, Leukemia, vol.24, issue.4, pp.900-903, 2010.

T. I. Mughal, N. C. Cross, E. Padron, R. V. Tiu, M. Savona et al., An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms, Haematologica, vol.100, issue.9, pp.1117-1147, 2015.

J. Vardiman, J. Bennett, B. Bain, I. Baumann, J. Thiele et al., World Health Organization Classification of tumours of haematopoietic and lymphoid tissues, 4 th ed

, Br J Haematol, vol.131, issue.2, pp.180-184, 2005.

J. Broseus, L. Florensa, E. Zipperer, S. Schnittger, L. Malcovati et al., Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis, Haematologica, vol.97, issue.7, pp.1036-1077, 2012.

K. Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata et al., Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.478, issue.7367, pp.64-73, 2011.

E. Papaemmanuil, M. Cazzola, J. Boultwood, L. Malcovati, P. Vyas et al., Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts, N Engl J Med, vol.365, issue.15, pp.1384-95, 2011.

F. Damm, F. Thol, O. Kosmider, S. Kade, P. Löffeld et al., SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications, Leukemia, vol.26, issue.5, pp.1137-1177, 2012.

L. Malcovati, E. Papaemmanuil, D. T. Bowen, J. Boultwood, D. Porta et al., Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms, Blood, vol.118, issue.24, pp.6239-6285, 2011.

S. Jeromin, T. Haferlach, V. Grossmann, T. Alpermann, A. Kowarsch et al., High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms, Haematologica, vol.98, issue.2, pp.15-22, 2013.

J. Broséus, T. Alpermann, M. Wulfert, F. Brichs, L. Jeromin et al., JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis, Leukemia, vol.27, issue.9, pp.1826-1857, 2013.

J. Broséus, E. Lippert, A. S. Harutyunyan, S. Jeromin, E. Zipperer et al., Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis, Leukemia, 2014.

V. Visconte, H. Makishima, A. Jankowska, H. Szpurka, F. Traina et al., SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts, Leukemia, vol.26, issue.3, pp.542-547, 2012.

J. Broséus, J. H. Park, S. Carillo, S. Hermouet, and F. Girodon, Presence of calreticulin mutations in JAK2-negative polycythemia vera, Blood, vol.124, issue.26, pp.3964-3970, 2014.

J. Broséus, E. Lippert, A. S. Harutyunyan, S. Jeromin, E. Zipperer et al., Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis, Leukemia, vol.28, issue.6, pp.1374-1380, 2014.

C. Guglielmi, F. Gomez, T. Philip, A. Hagenbeek, M. Martelli et al., Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial, J Clin Oncol, vol.16, issue.10, pp.3264-3273, 1998.

C. Thieblemont and C. Gisselbrecht, Second-line treatment paradigms for diffuse large B-cell lymphomas, Curr Oncol Rep, vol.11, issue.5, pp.386-93, 2009.

C. Gisselbrecht, B. Glass, N. Mounier, S. Gill, D. Linch et al., Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, vol.28, issue.27, pp.4184-90, 2010.

C. Thieblemont, J. Briere, N. Mounier, H. U. Voelker, W. Cuccuini et al., The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study, J Clin Oncol, vol.29, issue.31, pp.4079-87, 2011.

M. Roschewski, L. M. Staudt, and W. H. Wilson, Diffuse large B-cell lymphoma-treatment approaches in the molecular era, Nat Rev Clin Oncol, vol.11, issue.1, pp.12-23, 2014.

F. Jardin, Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy, Discov Med, vol.18, issue.97, pp.51-65, 2014.

L. H. Sehn and R. D. Gascoyne, Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity, Blood, vol.125, issue.1, pp.22-32, 2015.

A. J. Novak, Y. W. Asmann, M. J. Maurer, C. Wang, S. L. Slager et al., Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma, Blood Cancer J, vol.5, p.346, 2015.

S. Mareschal, S. Dubois, P. J. Viailly, P. Bertrand, E. Bohers et al., Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes Chromosomes Cancer, vol.55, issue.3, pp.251-67, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01237083

R. D. Morin, S. Assouline, M. Alcaide, A. Mohajeri, R. L. Johnston et al., Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas, Clin Cancer Res, vol.22, issue.9, pp.2290-300, 2016.

J. Broséus, G. Chen, S. Hergalant, G. Ramstein, N. Mounier et al., Relapsed diffuse large Bcell lymphoma present different genomic profiles between early and late relapses, Oncotarget, vol.7, issue.51, pp.83987-4002, 2016.

J. Broséus, S. Mourah, G. Ramstein, S. Bernard, N. Mounier et al., Oncotarget, vol.8, issue.53, pp.90808-90832, 2017.

S. Jeromin, T. Haferlach, S. Weissmann, M. Meggendorfer, C. Eder et al., Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations, Haematologica, vol.100, issue.4, pp.125-132, 2015.

M. M. Patnaik, T. L. Lasho, C. M. Finke, C. A. Hanson, R. L. King et al., Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing, Am J Hematol, vol.91, issue.5, pp.492-500, 2016.

A. S. Sperling, C. J. Gibson, and B. L. Ebert, The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia, Nat Rev Cancer, vol.17, issue.1, pp.5-19, 2017.

F. Delhommeau, S. Dupont, D. Valle, V. James, C. Trannoy et al., Mutation in TET2 in myeloid cancers, N Engl J Med, vol.360, issue.22, pp.2289-301, 2009.

V. Santini, A. Melnick, J. P. Maciejewski, E. Duprez, C. Nervi et al., Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents, Crit Rev Oncol Hematol, vol.88, issue.2, pp.231-276, 2013.

K. D. Rasmussen, G. Jia, J. V. Johansen, M. T. Pedersen, N. Rapin et al., Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis, Genes Dev, vol.29, issue.9, pp.910-932, 2015.

B. D. Cheson, P. L. Greenberg, J. M. Bennett, B. Lowenberg, P. W. Wijermans et al., Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, vol.108, issue.2, pp.419-444, 2006.

L. Shen, H. Kantarjian, Y. Guo, E. Lin, J. Shan et al., DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes, J Clin Oncol, vol.28, issue.4, pp.605-618, 2010.

K. Meldi, T. Qin, F. Buchi, N. Droin, J. Sotzen et al., Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia, J Clin Invest, vol.125, issue.5, pp.1857-72, 2015.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, vol.68, issue.1, pp.7-30, 2018.

J. L. Binet, M. Leporrier, G. Dighiero, D. Charron, D. 'athis et al., A clinical staging system for chronic lymphocytic leukemia: prognostic significance, Cancer, vol.40, issue.2, pp.855-64, 1977.

M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-cappio, G. Dighiero et al., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, issue.12, pp.5446-56, 2008.

M. Hallek, Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment, Am J Hematol, vol.92, issue.9, pp.946-65, 2017.

R. N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, vol.94, issue.6, pp.1840-1847, 1999.

T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, vol.94, issue.6, pp.1848-54, 1999.

H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber et al., Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med, vol.343, issue.26, pp.1910-1916, 2000.

P. Ouillette, R. Collins, S. Shakhan, J. Li, E. Peres et al., Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia, Blood, vol.118, issue.11, pp.3051-61, 2011.

J. Edelmann, K. Holzmann, F. Miller, D. Winkler, A. Bühler et al., High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations, Blood, vol.120, issue.24, pp.4783-94, 2012.

X. S. Puente, M. Pinyol, V. Quesada, L. Conde, G. R. Ordóñez et al., Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.475, issue.7354, pp.101-106, 2011.

V. Quesada, L. Conde, N. Villamor, G. R. Ordóñez, P. Jares et al., Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat Genet, vol.44, issue.1, pp.47-52, 2011.

D. A. Landau, S. L. Carter, P. Stojanov, A. Mckenna, K. Stevenson et al., Evolution and impact of subclonal mutations in chronic lymphocytic leukemia, Cell, vol.152, issue.4, pp.714-740, 2013.

X. S. Puente, S. Beà, R. Valdés-mas, N. Villamor, J. Gutiérrez-abril et al., Non-coding recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.526, issue.7574, pp.519-543, 2015.

D. A. Landau, E. Tausch, A. N. Taylor-weiner, C. Stewart, J. G. Reiter et al., Mutations driving CLL and their evolution in progression and relapse, Nature, vol.526, issue.7574, pp.525-555, 2015.

G. Lazarian, R. Guièze, and C. J. Wu, Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia, J Clin Oncol, vol.35, issue.9, pp.984-93, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01655956

T. Zenz, B. Eichhorst, R. Busch, T. Denzel, S. Häbe et al., TP53 mutation and survival in chronic lymphocytic leukemia, J Clin Oncol, vol.28, issue.29, pp.4473-4482, 2010.

D. Rossi, S. Rasi, G. Fabbri, V. Spina, M. Fangazio et al., Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia, Blood, vol.119, issue.2, pp.521-530, 2012.

S. Jeromin, S. Weissmann, C. Haferlach, F. Dicker, K. Bayer et al., SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.28, issue.1, pp.108-125, 2014.

S. Stilgenbauer, A. Schnaiter, P. Paschka, T. Zenz, M. Rossi et al., Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial, Blood, vol.123, issue.21, pp.3247-54, 2014.

P. Baliakas, A. Hadzidimitriou, L. A. Sutton, D. Rossi, E. Minga et al., Recurrent mutations refine prognosis in chronic lymphocytic leukemia, Leukemia, vol.29, issue.2, pp.329-365, 2015.

A. Schuh, J. Becq, S. Humphray, A. A. Burns, A. Clifford et al., Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns, Blood, vol.120, issue.20, pp.4191-4197, 2012.

G. Fabbri, S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian et al., Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation, J Exp Med, vol.208, issue.7, pp.1389-401, 2011.

D. Rossi, M. Fangazio, S. Rasi, T. Vaisitti, S. Monti et al., Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia, Blood, vol.119, issue.12, pp.2854-62, 2012.

D. Rossi, A. Bruscaggin, V. Spina, S. Rasi, H. Khiabanian et al., Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness, Blood, vol.118, issue.26, pp.6904-6912, 2011.

D. Rossi, S. Rasi, V. Spina, A. Bruscaggin, S. Monti et al., Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia, Blood, vol.121, issue.8, pp.1403-1415, 2013.

M. Messina, D. Giudice, I. Khiabanian, H. Rossi, D. Chiaretti et al., Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness, Blood, vol.123, issue.15, pp.2378-88, 2014.

R. Guièze, P. Robbe, R. Clifford, S. De-guibert, B. Pereira et al., Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL, Blood, vol.126, issue.18, pp.2110-2117, 2015.

V. Ljungström, C. D. Young, E. Pandzic, T. Mansouri, L. Plevova et al., Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations, Blood, vol.127, issue.8, pp.1007-1023, 2016.

S. Pospisilova, D. Gonzalez, J. Malcikova, M. Trbusek, D. Rossi et al., ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia, Leukemia, vol.26, issue.7, pp.1458-61, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02318055

A. Jethwa, J. Hüllein, T. Stolz, C. Blume, L. Sellner et al., Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia, Br J Haematol, vol.163, issue.4, pp.496-500, 2013.

D. Rossi, H. Khiabanian, V. Spina, C. Ciardullo, A. Bruscaggin et al., Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, vol.123, issue.14, pp.2139-2186, 2014.

L. A. Sutton, V. Ljungström, L. Mansouri, Y. E. , C. D. Navrkalova et al., Targeted nextgeneration sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting, Haematologica, vol.100, issue.3, pp.370-376, 2015.

F. Nadeu, J. Delgado, C. Royo, T. Baumann, T. Stankovic et al., Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia, Blood, vol.127, issue.17, pp.2122-2152, 2016.

S. Rasi, H. Khiabanian, C. Ciardullo, L. Terzi-di-bergamo, S. Monti et al., Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia, Haematologica, vol.101, issue.4, pp.135-143, 2016.

J. Malcikova, K. Stano-kozubik, B. Tichy, B. Kantorova, S. Pavlova et al., Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia, Leukemia, vol.29, issue.4, pp.877-85, 2015.

N. Winkelmann, M. Rose-zerilli, J. Forster, M. Parry, A. Parker et al., Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis, Haematologica, vol.100, issue.6, pp.237-246, 2015.

R. C. Jansen and J. P. Nap, Genetical genomics: the added value from segregation, Trends Genet, vol.17, issue.7, pp.388-91, 2001.

S. A. Monks, A. Leonardson, H. Zhu, P. Cundiff, P. Pietrusiak et al., Genetic inheritance of gene expression in human cell lines, Am J Hum Genet, vol.75, issue.6, pp.1094-105, 2004.

M. Morley, C. M. Molony, T. M. Weber, J. L. Devlin, K. G. Ewens et al., Genetic analysis of genome-wide variation in human gene expression, Nature, vol.430, issue.7001, pp.743-750, 2004.

J. Li and M. Burmeister, Genetical genomics: combining genetics with gene expression analysis, Hum Mol Genet, vol.14, issue.2, pp.163-172, 2005.

H. Müller-hermelink, E. Montserrat, D. Catovsky, E. Campo, N. Harris et al., Chronic lymphocytic leukemia/small lymphocytic lymphoma, WHO classification of tumours of haematopoietic and lymphoid tissues

E. Matutes, K. Owusu-ankomah, R. Morilla, G. Marco, J. Houlihan et al., The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, Leukemia, vol.8, issue.10, pp.1640-1645, 1994.

K. Stamatopoulos, C. Belessi, C. Moreno, M. Boudjograh, G. Guida et al., Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations, Blood, vol.109, issue.1, pp.259-70, 2007.

L. Wang, M. S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez et al., SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N Engl J Med, vol.365, issue.26, pp.2497-506, 2011.

M. Hallek, K. Fischer, G. Fingerle-rowson, A. M. Fink, R. Busch et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, Lancet, vol.376, issue.9747, pp.1164-74, 2010.

B. Eichhorst, A. M. Fink, J. Bahlo, R. Busch, G. Kovacs et al., First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, noninferiority trial, Lancet Oncol, vol.17, issue.7, pp.928-970, 2016.

K. Fischer, J. Bahlo, A. M. Fink, V. Goede, C. D. Herling et al., Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, vol.127, issue.2, pp.208-223, 2016.

R. Guièze and C. J. Wu, Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia, Blood, vol.126, issue.4, pp.445-53, 2015.

F. K. Stevenson, S. Krysov, A. J. Davies, A. J. Steele, and G. Packham, B-cell receptor signaling in chronic lymphocytic leukemia, Blood, vol.118, issue.16, pp.4313-4333, 2011.

J. A. Burger and N. Chiorazzi, B cell receptor signaling in chronic lymphocytic leukemia, Trends Immunol, vol.34, issue.12, pp.592-601, 2013.

R. Maffei, S. Fiorcari, S. Martinelli, L. Potenza, M. Luppi et al., Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib, J Hematol Oncol, vol.8, p.60, 2015.

R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel et al., Idelalisib and rituximab in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.370, issue.11, pp.997-1007, 2014.

T. Robak, S. Stilgenbauer, and A. Tedeschi, Front-line treatment of CLL in the era of novel agents, Cancer Treat Rev, vol.53, pp.70-78, 2017.

A. J. Souers, J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, vol.19, issue.2, pp.202-210, 2013.

A. W. Roberts, M. S. Davids, J. M. Pagel, B. S. Kahl, S. D. Puvvada et al., Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.374, issue.4, pp.311-333, 2016.

H. Huber, S. Edenhofer, S. Estenfelder, and S. Stilgenbauer, Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia, Onco Targets Ther, vol.10, pp.645-56, 2017.

S. Stilgenbauer, B. Eichhorst, J. Schetelig, S. Coutre, J. F. Seymour et al., Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, Lancet Oncol, vol.17, issue.6, pp.768-78, 2016.

J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka et al., Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib, N Engl J Med, vol.370, issue.24, pp.2286-94, 2014.

M. Kulis, S. Heath, M. Bibikova, A. C. Queirós, A. Navarro et al., Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia, Nat Genet, vol.44, issue.11, pp.1236-1278, 2012.

P. G. Ferreira, P. Jares, D. Rico, G. Gómez-lópez, A. Martínez-trillos et al., Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia, Genome Res, vol.24, issue.2, pp.212-238, 2014.

A. C. Queirós, N. Villamor, G. Clot, A. Martinez-trillos, M. Kulis et al., A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact, Leukemia, vol.29, issue.3, pp.598-605, 2015.

C. C. Oakes, R. Claus, L. Gu, Y. Assenov, J. Hüllein et al., DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia, Cancer Discov, vol.4, issue.3, pp.253-64, 2014.

A. M. Tsimberidou and M. J. Keating, Richter syndrome: biology, incidence, and therapeutic strategies, Cancer, vol.103, issue.2, pp.216-244, 2005.

A. M. Tsimberidou, S. O'brien, I. Khouri, F. J. Giles, H. M. Kantarjian et al., Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J Clin Oncol, vol.24, issue.15, pp.2343-51, 2006.

D. Rossi, M. Cerri, D. Capello, C. Deambrogi, F. M. Rossi et al., Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome, Br J Haematol, vol.142, issue.2, pp.202-217, 2008.

D. Rossi, V. Spina, C. Deambrogi, S. Rasi, L. Laurenti et al., The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, vol.117, issue.12, pp.3391-401, 2011.

D. Rossi, V. Spina, F. Forconi, D. Capello, M. Fangazio et al., Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis, Int J Cancer, vol.130, issue.12, pp.3006-3016, 2012.

S. A. Parikh, K. G. Rabe, T. G. Call, C. S. Zent, T. M. Habermann et al., Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients, Br J Haematol, vol.162, issue.6, pp.774-82, 2013.

R. Beekman, V. Chapaprieta, N. Russiñol, R. Vilarrasa-blasi, N. Verdaguer-dot et al., The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia, Nat Med, vol.24, issue.6, pp.868-80, 2018.

R. Küppers, Mechanisms of B-cell lymphoma pathogenesis, Nat Rev Cancer, vol.5, issue.4, pp.251-62, 2005.

S. A. Parikh, N. E. Kay, and T. D. Shanafelt, How we treat Richter syndrome, Blood, vol.123, issue.11, pp.1647-57, 2014.

K. Jamroziak, T. Tadmor, T. Robak, and A. Polliack, Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy, Leuk Lymphoma, vol.56, issue.7, pp.1949-58, 2015.

S. Aydin, D. Rossi, L. Bergui, D. 'arena, G. Ferrero et al., CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?, Blood, vol.111, issue.12, pp.5646-53, 2008.

D. Rossi, V. Spina, M. Cerri, S. Rasi, C. Deambrogi et al., Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome, Clin Cancer Res, vol.15, issue.13, pp.4415-4437, 2009.

D. Rossi, L. Bodoni, C. Genuardi, E. Monitillo, L. Drandi et al., Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia, Leukemia, vol.23, issue.6, pp.1062-72, 2009.

M. Fangazio, D. Paoli, L. Rossi, D. Gaidano, and G. , Predictive markers and driving factors behind Richter syndrome development, Expert Rev Anticancer Ther, vol.11, issue.3, pp.433-475, 2011.

D. Rossi, S. Rasi, V. Spina, M. Fangazio, S. Monti et al., Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome, Br J Haematol, vol.158, issue.3, pp.426-435, 2012.

S. A. Parikh and T. D. Shanafelt, Risk factors for Richter syndrome in chronic lymphocytic leukemia, Curr Hematol Malig Rep, vol.9, issue.3, pp.294-303, 2014.

M. Solh, K. R. Rai, B. L. Peterson, J. E. Kolitz, F. R. Appelbaum et al., The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011), Leuk Lymphoma, vol.54, issue.2, pp.252-256, 2013.

D. Catovsky, S. Richards, E. Matutes, D. Oscier, M. Dyer et al., Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial, Lancet, vol.370, issue.9583, pp.230-239, 2007.

E. Chigrinova, A. Rinaldi, I. Kwee, D. Rossi, P. M. Rancoita et al., Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome, Blood, vol.122, issue.15, pp.2673-82, 2013.

D. Rossi and . Xiii, Molecular pathogenesis of transformed lymphomas, Hematol Oncol, vol.33, issue.1, pp.70-74, 2015.

P. Langerbeins, R. Busch, N. Anheier, J. Dürig, M. Bergmann et al., Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation, Am J Hematol, vol.89, issue.12, pp.239-282, 2014.

A. M. Tsimberidou, W. G. Wierda, W. Plunkett, R. Kurzrock, S. O'brien et al., Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia, J Clin Oncol, vol.26, issue.2, pp.196-203, 2008.

A. M. Tsimberidou, W. G. Wierda, S. Wen, W. Plunkett, S. O'brien et al., Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome, Clin Lymphoma Myeloma Leuk, vol.13, issue.5, pp.568-74, 2013.

K. Cwynarski, A. Van-biezen, L. De-wreede, S. Stilgenbauer, D. Bunjes et al., Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation, J Clin Oncol, vol.30, issue.18, pp.2211-2218, 2012.

M. Tsang, T. D. Shanafelt, T. G. Call, W. Ding, A. Chanan-khan et al., The efficacy of ibrutinib in the treatment of Richter syndrome, Blood, vol.125, issue.10, pp.1676-1684, 2015.

M. Scandurra, D. Rossi, C. Deambrogi, P. M. Rancoita, E. Chigrinova et al., Genomic profiling of

, Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas, Hematol Oncol, vol.28, issue.2, pp.62-69, 2010.

G. Fabbri, H. Khiabanian, A. B. Holmes, J. Wang, M. Messina et al., Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome, J Exp Med, vol.210, issue.11, pp.2273-88, 2013.

A. Rinaldi, A. A. Mensah, I. Kwee, F. Forconi, E. M. Orlandi et al., Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma, Br J Haematol, vol.163, issue.2, pp.194-204, 2013.

M. Kulis, A. Merkel, S. Heath, A. C. Queirós, R. P. Schuyler et al., Whole-genome fingerprint of the DNA methylome during human B cell differentiation, Nat Genet, vol.47, issue.7, pp.746-56, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01163753

H. Kretzmer, S. H. Bernhart, W. Wang, A. Haake, M. A. Weniger et al., DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control, Nat Genet, vol.47, issue.11, pp.1316-1341, 2015.

A. C. Queirós, R. Beekman, R. Vilarrasa-blasi, M. Duran-ferrer, G. Clot et al., Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage, Cancer Cell, vol.30, issue.5, pp.806-827, 2016.

G. Chen, J. Broséus, S. Hergalant, A. Donnart, C. Chevalier et al., Identification of master genes involved in liver key functions through transcriptomics and epigenomics of methyl donor deficiency in rat: relevance to nonalcoholic liver disease, Mol Nutr Food Res, vol.59, issue.2, pp.293-302, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01755906

A. A. Alizadeh, M. B. Eisen, R. E. Davis, C. Ma, I. S. Lossos et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, issue.6769, pp.503-514, 2000.

B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, issue.4, pp.235-277, 2002.

P. Feugier, A. Van-hoof, C. Sebban, P. Solal-celigny, R. Bouabdallah et al., Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, vol.23, issue.18, pp.4117-4143, 2005.

M. Wilhelm, J. Schlegl, H. Hahne, A. M. Gholami, M. Lieberenz et al., Mass-spectrometrybased draft of the human proteome, Nature, vol.509, issue.7502, pp.582-589, 2014.

A. M. Gholami, H. Hahne, Z. Wu, F. J. Auer, C. Meng et al., Global proteome analysis of the NCI-60 cell line panel, Cell Rep, vol.4, issue.3, pp.609-629, 2013.

C. Vogel and E. M. Marcotte, Insights into the regulation of protein abundance from proteomic and transcriptomic analyses, Nat Rev Genet, vol.13, issue.4, pp.227-259, 2012.

A. Perrot, C. Pionneau, S. Nadaud, F. Davi, V. Leblond et al., A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia, Blood, vol.118, issue.4, pp.1-15, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02558548

L. A. Diaz and A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA, J Clin Oncol, vol.32, issue.6, pp.579-86, 2014.

E. Bohers, P. J. Viailly, S. Dubois, P. Bertrand, C. Maingonnat et al., Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis, Haematologica, vol.100, issue.7, pp.280-284, 2015.

M. Roschewski, K. Dunleavy, S. Pittaluga, M. Moorhead, F. Pepin et al., Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study, Lancet Oncol, vol.16, issue.5, pp.541-550, 2015.

D. M. Kurtz, M. R. Green, S. V. Bratman, F. Scherer, C. L. Liu et al., Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing, Blood, vol.125, issue.24, pp.3679-87, 2015.

V. Camus, N. Sarafan-vasseur, E. Bohers, S. Dubois, S. Mareschal et al., Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma, Leuk Lymphoma, vol.2016, pp.1-9
URL : https://hal.archives-ouvertes.fr/hal-02329919

M. Roschewski, L. M. Staudt, and W. H. Wilson, Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma, Blood, vol.127, issue.25, pp.3127-3159, 2016.

P. Yeh, T. Hunter, D. Sinha, S. Ftouni, E. Wallach et al., Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia, Nat Commun, vol.8, issue.5, pp.548-54, 2014.

A. M. Newman, A. F. Lovejoy, D. M. Klass, D. M. Kurtz, J. J. Chabon et al., Integrated digital error suppression for improved detection of circulating tumor DNA, Nat Biotechnol, vol.34, issue.5, pp.547-55, 2016.

F. Scherer, D. M. Kurtz, A. M. Newman, H. Stehr, A. F. Craig et al., Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA, Sci Transl Med, vol.8, issue.364, pp.364-155, 2016.

D. Rossi, F. Diop, E. Spaccarotella, S. Monti, M. Zanni et al., Diffuse large B-cell lymphoma genotyping on the liquid biopsy, Blood, vol.129, issue.14, pp.1947-57, 2017.

J. C. Byrd, R. R. Furman, S. E. Coutre, I. W. Flinn, J. A. Burger et al., Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.369, issue.1, pp.32-42, 2013.

J. A. Woyach, A. S. Ruppert, D. Guinn, A. Lehman, J. S. Blachly et al., J Clin Oncol, vol.35, issue.13, pp.1437-1480, 2017.

M. A. Anderson, C. Tam, T. E. Lew, S. Juneja, M. Juneja et al., Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax, Blood, vol.129, issue.25, pp.3362-70, 2017.

R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler et al., Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science, vol.321, issue.5891, pp.974-981, 2008.

M. S. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger et al., Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J Clin Oncol, vol.29, issue.18, pp.2493-2501, 2011.

M. S. Topp, N. Gökbuget, G. Zugmaier, P. Klappers, M. Stelljes et al., Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia, J Clin Oncol, vol.32, issue.36, pp.4134-4174, 2014.

H. Kantarjian, A. Stein, N. Gökbuget, A. K. Fielding, A. C. Schuh et al., Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, N Engl J Med, vol.376, issue.9, pp.836-883, 2017.

G. Martinelli, N. Boissel, P. Chevallier, O. Ottmann, N. Gökbuget et al., Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study, J Clin Oncol, vol.35, issue.16, pp.1795-802, 2017.

A. Viardot, M. E. Goebeler, G. Hess, S. Neumann, M. Pfreundschuh et al., Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma, Blood, vol.127, issue.11, pp.1410-1416, 2016.

W. Ding, B. R. Laplant, T. G. Call, S. A. Parikh, J. F. Leis et al., Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL, Blood, vol.129, issue.26, pp.3419-3446, 2017.

Z. Y. Xu-monette, J. Zhou, and K. H. Young, PD-1 expression and clinical PD-1 blockade in B-cell lymphomas, Blood, vol.131, issue.1, pp.68-83, 2018.

L. Malcovati, D. Porta, M. G. , P. D. Boveri, E. Pellagatti et al., Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Blood, vol.114, issue.17, pp.3538-3583, 2009.

E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo et al., The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, vol.108, issue.6, pp.1865-1872, 2006.

Y. Pikman, B. H. Lee, T. Mercher, E. Mcdowell, B. L. Ebert et al., MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia, PLoS Med, vol.3, issue.7, p.270, 2006.

T. L. Lasho, A. Pardanani, and A. Tefferi, LNK mutations in JAK2 mutation-negative erythrocytosis, N Engl J Med, vol.363, issue.12, pp.1189-90, 2010.

S. T. Oh, E. F. Simonds, C. Jones, M. B. Hale, Y. Goltsev et al., Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms, Blood, vol.116, issue.6, pp.988-92, 2010.

H. Makishima, H. Cazzolli, H. Szpurka, A. Dunbar, R. Tiu et al., Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies, J Clin Oncol, vol.27, issue.36, pp.6109-6125, 2009.

Y. Suessmuth, J. Elliott, M. J. Percy, M. Inami, H. Attal et al., A new polycythaemia veraassociated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses, Br J Haematol, vol.147, issue.4, pp.450-458, 2009.

J. Wang, G. Kong, Y. Liu, J. Du, Y. I. Chang et al., Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions, Blood, vol.121, issue.26, pp.5203-5210, 2013.

M. Brecqueville, J. Rey, F. Bertucci, E. Coppin, P. Finetti et al., Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms, Genes Chromosomes Cancer, vol.51, issue.8, pp.743-55, 2012.

C. P. Kratz, C. M. Niemeyer, R. P. Castleberry, M. Cetin, E. Bergsträsser et al., The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease, Blood, vol.106, issue.6, pp.2183-2188, 2005.

A. Tefferi, A. Pardanani, K. H. Lim, A. , O. Lasho et al., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, vol.23, issue.5, pp.905-916, 2009.

F. Stegelmann, L. Bullinger, R. F. Schlenk, P. Paschka, M. Griesshammer et al., DNMT3A mutations in myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1217-1226, 2011.

P. Guglielmelli, F. Biamonte, J. Score, C. Hidalgo-curtis, F. Cervantes et al., EZH2 mutational status predicts poor survival in myelofibrosis, Blood, vol.118, pp.5227-5261, 2011.

R. Bejar, K. Stevenson, A. , O. Galili, N. Nilsson et al., Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, vol.364, issue.26, pp.2496-506, 2011.

P. L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-manero et al., Revised international prognostic scoring system for myelodysplastic syndromes, Blood, vol.120, issue.12, pp.2454-65, 2012.

R. Itzykson, O. Kosmider, T. Cluzeau, V. Mansat-de-mas, F. Dreyfus et al., Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias, Leukemia, vol.25, issue.7, pp.1147-52, 2011.

A. Nazha, M. Narkhede, T. Radivoyevitch, D. J. Seastone, B. J. Patel et al., Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes, Leukemia, vol.30, issue.11, pp.2214-2234, 2016.

P. Fenaux, L. Ades, M. Fontenay, S. Raynaud, V. Eclache et al., French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group, Hématologie, vol.21, issue.1, pp.28-45, 2015.

A. Guerci-bresler, L. Ades, E. Gyan, M. Mohty, L. Legros et al., Recommandations pour l'utilisation de l'Azacitidine dans le traitement des syndromes myélodysplasiques de risque intermédiaire-2 ou élevé. Fiches pratiques du Groupe Francophone des, Myélodysplasies (GFM), issue.1, pp.1-8, 2010.

T. E. Fandy, J. G. Herman, P. Kerns, A. Jiemjit, E. A. Sugar et al., Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies, Blood, vol.114, issue.13, pp.2764-73, 2009.

R. Itzykson and P. Fenaux, Epigenetics of myelodysplastic syndromes, Leukemia, vol.28, issue.3, pp.497-506, 2014.

M. T. Cedena, I. Rapado, A. Santos-lozano, R. Ayala, E. Onecha et al., Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes, Oncotarget, vol.8, issue.63, pp.106948-61, 2017.

H. Wang, Y. Li, N. Lv, L. Wang, and L. Yu, Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes, Ann Hematol, vol.97, issue.11, pp.2025-2063, 2018.

M. Tobiasson, H. Abdulkadir, A. Lennartsson, S. Katayama, F. Marabita et al.,

, Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease, Oncotarget, vol.8, issue.17, pp.28812-28837, 2017.

S. Maegawa, S. M. Gough, N. Watanabe-okochi, Y. Lu, N. Zhang et al., Age-related epigenetic drift in the pathogenesis of MDS and AML, Genome Res, vol.24, issue.4, pp.580-91, 2014.

S. Li, F. E. Garrett-bakelman, S. S. Chung, M. A. Sanders, T. Hricik et al., Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia, Nat Med, vol.22, issue.7, pp.792-801, 2016.